LFCR News & Events

Lifecore announced it has signed a new agreement with a global pharmaceutical company. Under the terms of the agreement, Lifecore will perform technical transfer services to support the commercial production of an injectable suspension product for neurological disorders.

Lifecore announced that it has signed a manufacturing services agreement with a provider of ophthalmic disease management solutions. Under the terms of the agreement, Lifecore will perform process development and technical transfer services in support of anticipated commercial manufacturing upon regulatory approval. "We are pleased to announce another customer win and the opportunity to support an important new technical transfer program," said Paul Josephs, chief executive officer of Lifecore. "This agreement reflects Lifecore's recognized, technical expertise and specialized manufacturing capabilities in the ophthalmic injectables space."

Backs FY26 adjusted EBITDA view $20.5M-$25M. "Concurrently, we continue to optimize our organization through cost reductions, improved efficiencies, and elevated quality. I am energized by our achievements during the quarter and remain highly optimistic and committed to building on this momentum throughout the year," stated Paul Josephs, President and Chief Executive Officer of Lifecore.